5 completed, 5 recruiting, 3 unknown, 2 active not recruiting. 17 Phase 2, 7 Phase 1, 1 Phase 3.
Follow Ovarian Cancer Recurrent: new trials by email Literature Review of Ovarian Cancer Recurrent trials Research Report on Ovarian Cancer Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse) Secondary cytoreductive surgery, Platinum Based Chemotherapy - Ovarian Cancer Recurrent, Platinum Sensitive Ovarian Cancer | Phase 2 | Not yet recruiting | Asan Medical Center | 160 | 2025-12-15 | 2025-12-19 |
| A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer COM701, Normal Saline - Ovarian Cancer, Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Active not recruiting | Compugen Ltd | 60 | 2025-07-21 | 2026-10-06 |
| A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003). Raludotatug Deruxtecan, Carboplatin, Paclitaxel - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 605 | 2025-04-15 | 2026-10-30 |
| Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer Pegylated liposomal doxorubicin plus adebrelimab with mirabegron, Pegylated liposomal doxorubicin plus adebrelimab - Ovarian Cancer Recurrent | Phase 2 / Phase 3 | Recruiting | Obstetrics & Gynecology Hospital of Fudan University | 296 | 2025-03-18 | 2025-03-18 |
| SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy Niraparib oral capsule, SBRT - Ovarian Cancer Recurrent | Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 42 | 2024-06-20 | 2026-07-13 |
| IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin - Ovarian Cancer Recurrent | Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 168 | 2022-09-06 | 2025-04-30 |
| Microtransplantation for Ovarian Cancer microtransplantation, HLA-mismatched donor peripheral stem cell infusion - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Unknown | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 60 | 2021-10-01 | 2021-10-27 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) ELU001 - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Elucida Oncology | 79 | 2021-09-13 | 2024-08-07 |
| Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer Bevacizumab, Tocotrienol - Ovarian Cancer Recurrent | Phase 2 | Completed | Vejle Hospital | 20 | 2019-10-29 | 2025-01-03 |
| Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) Surgery, carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin..., Niraparib - Ovarian Cancer Recurrent, Fallopian Tube Cancer | Phase 2 | Recruiting | Shanghai Gynecologic Oncology Group | 167 | 2019-10-18 | 2022-03-18 |
| Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer Rintatolimod, Pembrolizumab, Cisplatin - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Active not recruiting | Robert Edwards | 24 | 2019-01-28 | 2026-02-12 |
| Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors SHR-1210, Famitinib - Renal Cell Carcinoma, Urothelial Carcinoma | Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 265 | 2019-01-23 | 2022-07-01 |
| Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer Tumor Infiltrating Lymphocytes (TIL), Interferon Alfa 2A, Carboplatin - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Unknown | Leiden University Medical Center | 12 | 2018-08-01 | 2021-04-01 |
| DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer DCVAC/OvCa, Standard of Care Chemotherapy - Ovarian Cancer Recurrent | Phase 2 | Completed | SOTIO a.s. | 33 | 2017-11-23 | 2021-04-21 |
| EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer EP-100, Paclitaxel - Ovarian Cancer Recurrent | Phase 2 | Completed | Esperance Pharmaceuticals Inc | 49 | 2012-02-01 | 2014-06-10 |
| Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel Ombrabulin (AVE8062), Placebo, Paclitaxel - Ovarian Cancer Recurrent | Phase 2 | Completed | Sanofi | 154 | 2011-05-01 | 2015-12-21 |
| A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse Lenalidomide - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Completed | ARCAGY/ GINECO GROUP | 67 | 2009-05-01 | 2016-03-17 |
Ovarian Neoplasms (4) · Fallopian Tube Neoplasms (3) · Endometrial Neoplasms (2) · Carcinoma (1) · Carcinoma, Endometrioid (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Krukenberg Tumor (1) · Ovarian Diseases (1) · Recurrence (1) · Uterine Cervical Neoplasms (1) · Uterine Diseases (1)
Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Genital Diseases (6) · Genital Diseases, Female (6) · Genital Neoplasms, Female (6) · Neoplasms (6) · Neoplasms by Site (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Adnexal Diseases (5) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Gonadal Disorders (4) · Fallopian Tube Diseases (3) · Ovarian Diseases (3)
Carboplatin (5) · Paclitaxel (5) · liposomal doxorubicin (3) · 1-dodecylpyridoxal (2) · Bevacizumab (2) · Gemcitabine (2) · niraparib (2) · pembrolizumab (2) · AC 7700 (1) · Cisplatin (1) · EP-100 membrane-disrupting peptide (1) · Interferon alpha-2 (1) · Lenalidomide (1) · Maintenance (1) · Platinum Compounds (1)
ARCAGY/ GINECO GROUP (1) · Asan Medical Center (1) · Compugen Ltd (1) · Elucida Oncology (1) · Esperance Pharmaceuticals Inc (1) · Institute of Cancer Research, United Kingdom (1) · InxMed (Shanghai) Co., Ltd. (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Leiden University Medical Center (1) · Merck Sharp & Dohme LLC (1) · Obstetrics & Gynecology Hospital of Fudan University (1) · Robert Edwards (1) · SOTIO a.s. (1) · Sanofi (1) · Shanghai Gynecologic Oncology Group (1)
United States (6) · China (5) · France (3) · Czechia (2) · Israel (2) · Spain (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Canada (1) · Denmark (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1)
Dae-Yeon Kim (1) · Dingwei Ye, MD (1) · Harald Fricke, MD, PhD (1) · Judith Kroep, MD, PhD (1) · Lingying WU (1) · Robert Edwards, MD (1) · Rongyu Zang, M.D., Ph.D. (1) · Susana Banerjee (1) · Tingyan Shi, M.D., Ph.D. (1) · Torben F Hansen, MD, DMSc (1) · Xiaohua Wu, MD (1)
PMID 25210017, PMID 32319233, PMID 35017154, PMID 35537782, PMID 36481736
2017 (1)